Skip to main
  1. Stocks
  2. Insmed
  3. Forecast
INSM

Insmed (INSM) Stock Forecast & Price Target

Insmed (INSM) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Insmed is well positioned because BRINSUPRI has converted a long-ignored market into a real commercial franchise, becoming the first and only FDA-approved therapy for non-cystic fibrosis bronchiectasis and already surpassing $1B in revenue within its first four full quarters. Strong 3Q26 results reinforced that thesis, with total revenue of $524.4M, BRINSUPRI revenue of $400.1M, ARIKAYCE revenue of $124.4M, and raised 2026 guidance of $1.35B-$1.4B for BRINSUPRI and $460M-$470M for ARIKAYCE. Beyond the launch, the company has multiple additional value drivers in a >$6B TPIP program, expanded ARIKAYCE opportunity, and a large U.S. bronchiectasis population of roughly 500K-550K diagnosed patients, supporting a positive long-term outlook.

Bears say

Insmed is facing a weaker fundamental setup because the stock depends heavily on Brinsupri commercialization, yet the company has not disclosed persistence data and new patient starts may slow below the guided ~7,000 per quarter as the initial backlog is absorbed. Arikayce adds risk despite a 2026 estimate of $467M and U.S. list price of $220,012 per patient-year, because slower frontline adoption, softer refractory demand, and guideline timing uncertainty could limit the modeled 17% lower peak to $1.5B in 2034. The outlook is further pressured by a heavier cost structure, with 2027 R&D of $1,022M and SG&A of $1,133M, multiple concurrent TPIP Phase 3 launches, and a 2027 EPS estimate cut to $1.24 from $3.26.

Insmed (INSM) has been analyzed by 20 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.

Insmed (INSM) Analyst Forecast & Price Prediction

Get the latest Insmed (INSM) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Insmed (INSM)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insmed (INSM) Forecast

Analysts have given Insmed (INSM) a Buy based on their latest research and market trends.

According to 20 analysts, Insmed (INSM) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $203.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $203.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insmed (INSM)


Insmed (INSM) Analyst Forecast & Price Prediction

Get the latest Insmed (INSM) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Insmed (INSM)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover INSM stock data and trends